Drug intelligence / Profile preview

NC-034

Development stage: Preclinical
Lead developer: NodCure

Overview

NC-034 is a preclinical therapeutic candidate being developed by NodCure for the treatment of bone and joint disorders. As of early 2024, the program is in the discovery and preclinical stages, with development milestones projected through 2026. While specific details regarding its molecular target and modality have not been publicly disclosed, the company's name suggests a focus on the Nucleotide-binding oligomerization domain (NOD) pathway, which is involved in innate immune signaling and inflammation.

Beyond the preview

Go deeper on NC-034.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NC-034.

Explore the full profile